TABLE OF DEFINED TERMS Term Section
Table of Definitions Each of the following terms is defined in the Section set forth opposite such term: Acceptable Confidentiality Agreement Section 6.4(b)(i) Agreement Preamble Award Amendments Section 6.2(c) Book-Entry Shares Section 3.2(c) Certificate Section 3.2(c) Certificate of Merger Section 2.3 Closing Section 2.2 COBRA Section 4.18(d) COD Amendment Section 6.2(b) Code Recitals Company Preamble Company Board Recitals Company Board Recommendation Section 6.5 Company Capitalization Date Section 4.5(a) Company DSU Section 3.8(b) Company Indemnified Party Section 7.4(a) Company Material Contract Section 4.20(a) Company Plan Section 4.18(a) Company Preferred Stock Section 4.5(a) Company Real Property Section 4.14(b) Company Restricted Share Section 3.8(a) Company SEC Documents Section 4.7(a) Company Securities Section 4.5(e) Company Special Committee Recitals Company Stockholders’ Meeting Section 6.5 Company Subsidiary Securities Section 4.6(b) Company Termination Fee Section 10.3(a) Company Transaction Litigation Section 8.8 Continuing Employee Section 7.6(b) Convertible Note Amendments Section 6.2(a) D&O Insurance Section 7.4(b) DGCL Section 2.1(a) Effective Time Section 2.3 End Date Section 10.1(b)(i) Exchange Agent Section 3.6(a) Exchange Fund Section 3.6(a) Exchange Ratio Section 3.2(b) Expenses Section 10.3(c) Financing Section 8.2(a) Foreign Company Plan Section 4.18(a) Information Statement Section 8.3 Internal Controls Section 4.7(g) Merger Consideration Section 3.2(b) Merger Recitals Merger Sub Inc. Preamble Multiemployer Plan Section 4.18(c) Owned Real Property Section 4.14(a) Parent Preamble Parent Board Recitals Parent Class B Common Stock Section 5.5(a) Parent Preferred Stock Section 5.5(a) Parent RSUs Section 5.5(a) Parent SEC Documents Section 5.6(a) Parent Securities Section 5.5(b) Parent Special Committee Recitals Party or Parties Preamble Plan Termination Notice Section 7.6(c) Premium Cap Section 7.4(b) Proxy Statement Section 8.3 RDO Warrants Section 1.1 Real Property Leases Section 4.14(b) Registration Statement Section 8.3 Representatives Section 8.6(a) Rollover Warrants Section 3.9 Series A Preferred Stock Section 4.5(a) Solvent Section 5.10
Use of Defined Terms Unless otherwise defined or the context otherwise requires, terms for which meanings are provided in this Agreement shall have such meanings when used in each other Loan Document and the Disclosure Schedule.
Glossary of Defined Terms The following terms, when used in this Agreement, have the meanings ascribed to them in the corresponding Sections of this Agreement listed below:
INDEX OF DEFINED TERMS Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(c) Closing 1.5 Closing Amount Recitals Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.